Menu Search
Equities

Avid Bioservices Inc

CDMO:NAQ

Avid Bioservices Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.30
  • Today's Change0.05 / 0.41%
  • Shares traded2.22m
  • 1 Year change+126.10%
  • Beta1.4344
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Avid Bioservices Inc's revenues fell -6.27% from 149.27m to 139.91m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 259.00k to a loss of 140.75m.
Gross margin6.27%
Net profit margin-101.27%
Operating margin-14.66%
Return on assets-37.08%
Return on equity-115.84%
Return on investment-57.59%
More ▼

Cash flow in USDView more

In 2024, Avid Bioservices Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 20.07m or 14.34% of revenues. In addition the company generated 10.95m in cash from operations while cash used for investing totalled 31.81m.
Cash flow per share-2.09
Price/Cash flow per share--
Book value per share0.9192
Tangible book value per share0.9192
More ▼

Balance sheet in USDView more

Avid Bioservices Inc has a Debt to Total Capital ratio of 73.43%, a higher figure than the previous year's 0.75%.
Current ratio1.46
Quick ratio1.05
Total debt/total equity2.76
Total debt/total capital0.7343
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.